Morgan Stanley Clene Inc. Transaction History

Morgan Stanley

$1.27 Trillion
Q2 2024

A detailed history of Morgan Stanley transactions in Clene Inc. stock. As of the latest transaction made, Morgan Stanley holds 338,635 shares of CLNN stock, worth $2.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

338,635

Previous 338,635 -0.0%

Holding current value

$2.07 Million

Previous $145,000 16.55%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.26 - $0.55 $520 - $1,100	-2,000 Reduced 0.59%	338,635 $101,000
Q3 2023 Nov 15, 2023	BUY	$0.46 - $0.87 $460 - $870	1,000 Added 0.29%	340,635 $170,000
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.22 $260,009 - $406,682	333,346 Added 5300.46%	339,635 $298,000
Q1 2023 May 15, 2023	SELL	$0.95 - $1.62 $9,932 - $16,937	-10,455 Reduced 62.44%	6,289 $7,000
Q4 2022 Feb 14, 2023	BUY	$0.92 - $40.2 $3,127 - $136,639	3,399 Added 25.47%	16,744 $16,000
Q3 2022 Nov 14, 2022	SELL	$0.33 - $73.0 $15,972 - $3.53 Million	-48,402 Reduced 78.39%	13,345 $37,000
Q2 2022 Oct 27, 2022	SELL	$2.1 - $4.12 $75,247 - $147,627	-35,832 Reduced 36.72%	61,747 $156,000
Q2 2022 Aug 15, 2022	SELL	$2.1 - $4.12 $75,247 - $147,627	-35,832 Reduced 36.72%	61,747 $156,000
Q1 2022 Oct 27, 2022	BUY	$2.42 - $4.42 $86,713 - $158,377	35,832 Added 58.03%	97,579 $385,000
Q1 2022 May 13, 2022	BUY	$2.42 - $4.42 $73,326 - $133,926	30,300 Added 45.04%	97,579 $385,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $7.53 $182,885 - $348,639	46,300 Added 220.7%	67,279 $276,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $143,286 - $284,894	20,979 New	20,979 $143,000

Others Institutions Holding CLNN

# of Institutions

Shares Held

6.22M

Call Options Held

287K

Put Options Held

162K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $388M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account